Archive for August, 2009|Monthly archive page
baptist, christian, destruct, embryo, federal, funding, NIH, OBAMA
In RELIGION & STEM CELLS on August 31, 2009 at 12:51 pm
Baptist Press – Federal suit challenges stem cell funding guidelines – News with a Christian Perspective
Posted on Aug 28, 2009 | by Tom Strode
WASHINGTON (BP)–The Obama administration’s guidelines for federal funding of stem cell research that results in the destruction of human embryos have been challenged in court, and a lawyer behind the suit says he thinks its “chances are very good.”
The National Institutes of Health’s decision to fund embryonic stem cell research is “unethical, scientifically unnecessary, fiscally irresponsible and counterproductive,” opponents said in their complaint filed Aug. 19 in District of Columbia federal court.
Their suit contends the guidelines violate a 13-year-old congressional ban on funds for research that destroys embryos. It also says the National Institutes of Health (NIH) failed to follow procedures required by law before issuing the guidelines, including in its dismissal of substantial studies that show other stem cells are “ethically and medically superior alternatives.” …
via Baptist Press – Federal suit challenges stem cell funding guidelines – News with a Christian Perspective.
CELL, daines, fund, gove, governor, million, new york, ny, paterson, RESEARCH, STEM
In BUSINESS OF STEM CELLS on August 31, 2009 at 12:49 pm
Monday, August 31, 2009, 8:18am EDT
New York plans to invest $20.4 million in stem-cell research.
Gov. David Paterson announced that $5.4 million will be earmarked to recruit research fellows to research institutions in New York. The remaining $15.4 million will be used to establish “multi-institutional research facilities” that will be shared by researchers from across the state.
“Investment in stem cell research is part of our vision to make New York a global leader in the new economy,” Paterson said.
New York State Health Commissioner Richard Daines, who is also the chair of the Empire State Stem Cell Board, said the funding will “ensure the best and the brightest new stem-cell investigators conduct their research in New York state.”
The governor put out two Requests for Applications. More detail on the applications, which are due Dec. 1, is available at the state’s Web site.
via NY commits $20M to stem-cell research – Business First of Buffalo:.
c-peptide, CELL, CURE, DIABETES, HA1c, insulin, PATIENT, STEM, STUDY, TREAT, trial
In VICTORIES & SUCCESS STORIES on August 31, 2009 at 12:12 pm
Can stem cells cure Diabetes – type 2? See the results of this one year study of adult stem cell treatment of Diabetes type – 2. C-peptide levels, insulin levels, insulin dosage requirements and HA1c levels.
v http://zoacell.com/investor/ascsummary.aspx
ADULT, CURE, DIABETES, HA1c, insulin, peptide, REPAIR, STUDY, trial
In VICTORIES & SUCCESS STORIES on August 31, 2009 at 12:00 pm
Can stem cells cure Diabetes – type 1? See the results of this one year study of adult stem cell treatment of Diabetes type – 1. C-peptide levels, insulin levels, insulin dosage requirements and HA1c levels.
ADULT, c-peptide, CELL, diabete, HA1c, hemoglobin, insulin, REPAIR, STEM, STUDY, trial
In VICTORIES & SUCCESS STORIES on August 31, 2009 at 11:51 am
One-year results for Repair Stem Cell treatments of diabetics.
Type one – click link or picture for larger images – http://repairstemcell.wordpress.com/2009/08/31/can-stem-cells-cure-diabetes-type-1/
Type 2 - click link or picture for larger images http://repairstemcell.wordpress.com/2009/08/31/can-stem-cells-cure-diabetes-type-2/
ADULT, BLIND, CELL, EYE, heal, iPS, madison, retina, skin, STEM, TREAT, wallace, wisconsin
In STEM CELLS IN THE NEWS on August 31, 2009 at 11:44 am
New insights on eye stem cells
Retinal stem cell – Wallace group Retinal stem cells have now been created from human skin, adding yet another specialized cell type to a rapidly growing list of cells that can be created using induced pluripotent (iPS) methodology. The finding could prove to be an important method in the production of human retinal cells, which would help overcome one of the greatest obstacles to successful stem cell therapies to treat eye conditions. The announcement was made on Monday by a team from the University of Wisconsin-Madison.
via Stem Cell Network Blog: New insights on eye stem cells.
armani, BUSH, cavalli, chanel, chloe, cicciolina, cut, fashion, grand, gucci, hirst, new york, pop, prada, rodarte, thatcher, tisci, vitton, zhukova
In STEM CELLS IN THE NEWS on August 31, 2009 at 11:42 am
Rodarte Celebrates Stem-Cell Scientists in the New Issue of Pop – The Cut – New York Magazine’s Fashion Blog
* 8/31/09 at 09:45 AM
Tomorrow, newsstands welcome the new issue of Pop, the first under editor-in-chief Dasha Zhukova, who was hired in February to replace the inimitable Katie Grand. Despite Pop being first and foremost a fashion magazine under Grand, Zhukova has confessed fashion isn’t really her thing. She is more a member of the art world than the fashion world, which is filled with (possibly resentful) editors who scoffed at her appointment during the fall 2009 season. One of the 28-year-old Zhukova’s most notable accomplishments thus far is the Garage Centre for Contemporary Culture, the contemporary art gallery in Moscow she opened a year ago. So she’s intent on making Pop just as much about art as fashion, according to WWD. The new issue has two covers, pictured here (not four, as previously rumored), with artwork by Damien Hirst.
The covers have received mixed reactions, but can the content inside the magazine appease naysayers? Riccardo Tisci dressed Cicciolina, presumably for a photo spread, for the issue. Barbara Bush (probably junior, not senior, but could you imagine?) interviewed the president of Liberia. Margaret Thatcher is celebrated as a fashion icon. And Rodarte “celebrate U.S. stem-cell scientists” in another photo shoot. Generally, we find fashion magazines are at their best when they make no sense yet so much sense at the same time. (Drag spreads and bizarre hats also help.) Pop sounds either weird enough to work or not weird enough at all. But advertisers are onboard: The 316-page issue includes ads by Prada, Dior, Louis Vuitton, Gucci, Chanel, Armani, Chloé, Mulberry, Tod’s, and Roberto Cavalli.
via Rodarte Celebrates Stem-Cell Scientists in the New Issue of Pop — The Cut: New York Magazine’s Fashion Blog.
biotech, CELL, investor, ipo, isaev, moscow, RUSSIA, STEM, stock, trade
In BUSINESS OF STEM CELLS on August 31, 2009 at 11:38 am
Investors look for upside as stem cell specialists prepare to list
31 August, 2009, 10:24
The Institute of Human Stem Cells is about to see one of Russia’s first biotechnology IPO’s in its attempt to boost the Russian stem cell storage market.
Finding a cure for previously incurable diseases – stem cell technology is pushing back the frontiers of medicine. Just how the potential of stem cell technology can be practically utilized is still undefined, but its promise is already obvious .
Stem cells are stored in stem cell banks – the Institute of Human Stem Cells in Moscow has over 50% of the Russian market.
Compared to other countries, the market has a vast growth potential, and the institute has formed a company to market its services. It’s storing stem cells and using them to develop new treatment methods.
The company is preparing for an IPO in the autumn, and is hoping to float from 15 to 25% of its shares to raise just under $5 million dollars, according to Head, Artur Isaev.
“Out cash flow comes from storing stem cells, but we also have an R and D section where we work on developing drugs. Our aim is to use the material in creating drugs and methods for curing certain diseases. If we succeed in that – our capitalisation could grow many- fold.”
via Investors look for upside as stem cell specialists prepare to list – RT.
ADULT, biolife, blfs, BLOOD, bloodstor, CELL, cord, embryo, STEM, store
In BUSINESS OF STEM CELLS on August 31, 2009 at 11:31 am
BloodStor(TM) Stem Cell Biopreservation Media Platform Launched by BioLife Solutions
Posted on: Monday, 31 August 2009, 05:00 CDT
BOTHELL, Wash., Aug. 31 /PRNewswire-FirstCall/ — BioLife Solutions, Inc. (OTC Bulletin Board: BLFS), a leading developer, manufacturer, and marketer of biopreservation tools for cells, tissues, and organs, today announced the launch of its BloodStor biopreservation media product platform. The product family includes BloodStor 55-5 for cryopreservation of umbilical cord blood stem cells, as well as other variants for peripheral blood derived stem cells. BloodStor 55-5, packaged in standard, single-use sterile vials of various fill volumes, is formulated with 55% USP grade DMSO and 5% USP grade dextran-40 in water for injection quality (WFI) water and supports a common cord blood processing protocol.
Mike Rice, BioLife’s chairman and CEO, noted, “The launch of our BloodStor product family supports our mission to become the leading provider of preservation tools for cells, tissues, and organs. Specifically, our BloodStor product offering should enable BioLife to more quickly capture a larger share of the demand for preservation media products used in the rapidly growing cord blood banking industry. We’re leveraging our Quality System and the capacity of our recently validated internal manufacturing facility to offer more standard and custom products to our strategic markets. We’ve already received orders for BloodStor 55-5 and expect to begin customer shipments by the end of September.”
via BloodStor(TM) Stem Cell Biopreservation Media Platform Launched by BioLife Solutions – Health News – redOrbit.
als, brainstorm, CELL, huntington, ISRAEL, MS, parkinson, STEM, stroke, tel aviv, thera
In BUSINESS OF STEM CELLS on August 31, 2009 at 11:29 am
BrainStorm Cell Therapeutics Taps Israeli CMO for Stem Cell Production
GEN News Highlights
BrainStorm Cell Therapeutics inked a deal with Israeli firm Protein Production Services for cGMP production of its stem cell therapeutic for amyotrophic lateral sclerosis (ALS). The clinical-grade product will be used in a preclinical safety trial.
“As we announced on August 24 after securing new funding, BrainStorm now has both the financing and the production capabilities to achieve our goal of reaching human clinical studies in the coming year,” notes Rami Efrati, CEO.
BrainStorm’s technology allows for the differentiation of bone marrow-derived stem cells into functional neurons and astrocytes, as demonstrated in animal models. It has reportedly been tested on various animal models of neurodegenerative diseases.
The firm’s current focus is on ALS and Parkinson’s. The technology can be leveraged for treating other diseases including MS, Huntington’s disease, and stroke, according to BrainStorm Cell Therapeutics.
The company holds rights to develop and commercialize the technology through an exclusive, worldwide licensing agreement with Ramot at Tel Aviv University, the technology transfer arm of the university.
via News: BrainStorm Cell Therapeutics Taps Israeli CMO for Stem Cell Production ..
